

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

Baseline malaria infection status and RTS,S/AS01E malaria vaccine efficacy

Michal Juraska^{*a,1}, Ph.D., Angela M. Early^{a,2}, Ph.D., Li Li¹, Ph.D., Stephen F. Schaffner², Ph.D., Marc Lievens³, M.Sc., Akanksha Khorgade², M.Sc., Brian Simpkins¹, B.A., Nima S. Hejazi⁴, Ph.D., David A. Benkeser⁵, Ph.D., Qi Wang, B.Eng.⁶, Laina D. Mercer⁷, Ph.D., Samuel Adjei⁸, M.B., Ch.B., D.T.M., Tsiri Agbenyega⁸, M.B., Ch.B., Ph.D., Scott Anderson², B.S., Daniel Ansong⁸, M.B., Ch.B., F.W.A.C.P., Dennis K. Bii⁹, M.B.Ch.B, M.P.H., Patrick B.Y. Buabeng⁸, M.B.A., Sean English², B.S., Nicholas Fitzgerald², B.S., Jonna Grimsby², Ph.D, Simon K. Kariuki⁹, Ph.D., Kephias Otieno⁹, M.Sc., François Roman³, M.D., Aaron M. Samuels^{10,11}, M.D., Nelli Westercamp¹¹, Ph.D., Christian F. Ockenhouse⁷, M.D., Ph.D., Opokua Ofori-Anyinam³, Ph.D., Cynthia K. Lee⁷, Ph.D., Bronwyn L. MacInnis², Ph.D., Dyann F. Wirth^{2,12}, Ph.D., Peter B. Gilbert^{1,13}, Ph.D., Daniel E. Neafsey^{*2,12}, Ph.D.

^a These authors contributed equally to this manuscript

1. Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, WA, USA

2. Broad Institute, Infectious Disease and Microbiome Program, Cambridge, MA, USA

3. GSK, Wavre, Belgium

4. Harvard T.H. Chan School of Public Health, Department of Biostatistics, Boston, MA, USA

5. Rollins School of Public Health, Department of Biostatistics and Bioinformatics, Atlanta, GA, USA

6. Department of Statistics, University of Washington, Seattle, WA, USA

7. PATH, Seattle, WA, USA

8. Kwame Nkrumah University of Science and Technology/Agogo Presbyterian Hospital, Agogo, Asante Akyem, Ghana

9. Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya

10. Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Kisumu, Kenya

11. Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, GA, USA

41

42 12. Harvard T.H. Chan School of Public Health, Department of Immunology and Infectious
43 Diseases, Boston, MA, USA

44

45 13. Department of Biostatistics, University of Washington, Hans Rosling Center for Population
46 Health, Seattle, WA, USA

47

48 * To whom reprint requests should be addressed

49 **Corresponding authors:**

50 Michal Juraska (mjuraska@fredhutch.org); Daniel E. Neafsey (neafsey@broadinstitute.org)

51

52

53 **Abstract**

54 **Background**

55 The only licensed malaria vaccine, RTS,S/AS01_E, confers moderate protection against
56 symptomatic disease. Because many malaria infections are asymptomatic, we conducted a
57 large-scale longitudinal parasite genotyping study of samples from a clinical trial exploring how
58 vaccine dosing regimen affects vaccine efficacy (VE).

59 **Methods**

60 1,500 children aged 5–17 months were randomized to receive four different RTS,S/AS01_E
61 regimens or a rabies control vaccine in a phase 2b clinical trial in Ghana and Kenya. We
62 evaluated the time to the first new genotypically detected infection and the total number of new
63 infections during two follow-up periods in over 36K participant specimens. We performed a post
64 hoc analysis of VE based on malaria infection status at first vaccination and force of infection.

65 **Results**

66 We observed significant and comparable VE (25–43%, 95% CI union 9–53%) against first new
67 infection for all four RTS,S/AS01_E regimens across both follow-up periods (12 and 20 months).
68 Each RTS,S/AS01_E regimen significantly reduced the number of new infections in the 20-month
69 follow-up period (control mean 4.1 vs. RTS,S/AS01_E mean 2.6–3.0). VE against first new
70 infection was significantly higher in participants who were malaria-infected (68%; 95% CI, 50 to
71 80%) versus uninfected (37%; 95% CI, 23 to 48%) at the first vaccination (P=0.0053) and in
72 participants experiencing greater force of infection between dose 1 and 3 (P=0.059).

73 **Conclusions**

74 All tested dosing regimens blocked some infections to a similar degree. Improved VE in
75 participants infected during vaccination could suggest new strategies for highly efficacious
76 malaria vaccine development and implementation. (ClinicalTrials.gov number, NCT03276962)

77

78 **Introduction**

79 Malaria infection by the *Plasmodium falciparum* parasite causes over 230 million cases and
80 600,000 deaths per year, and progress in reducing morbidity and mortality through vector
81 control and drug treatment has stalled.¹ RTS,S/AS01_E (hereafter referred to as RTS,S; GSK,
82 Wavre, Belgium) is the first vaccine recommended for *P. falciparum* malaria by the World Health
83 Organization and it provides moderate protective efficacy against clinical malaria. Improving
84 protective efficacy is a major goal of ongoing work, including testing alternative dosing
85 schedules and gaining a greater understanding of the mechanism of protection.

86 Most malaria vaccine trials evaluate vaccine efficacy (VE) using clinical disease as an
87 endpoint, but enhanced understanding of the mechanism and magnitude of protection may be
88 gained from molecular detection of new infections, given that a large proportion of malaria
89 infections are asymptomatic.² Here we report on the MAL-095 study, a genotyping investigation
90 of infection endpoints employing samples from the MAL-094 phase 2b randomized controlled
91 trial of RTS,S. The MAL-094 trial enrolled 5-17 month-old children in Ghana and Kenya and
92 used clinical disease endpoints to investigate the effect of dosing regimen on VE, ultimately
93 finding no significant differences in VE against clinical disease between a delayed third dose
94 regimen (R017), a fractional third dose regimen (Fx012), and the standard full dose regimen
95 (R012).³

96 To explore protection in that study using a molecular infection endpoint, we genotyped >
97 36,000 blood samples taken both at symptomatic clinic visits and at monthly cross-sectional
98 timepoints. We used a genotyping assay that detects infections at a sub-microscopic level and
99 distinguishes newly incident superinfections from persistent asymptomatic infections, yielding
100 the capacity to measure both the time to first new infection and the cumulative number of new
101 parasite infections post-vaccination. We additionally assessed VE according to genotype of the
102 infecting parasites given the previous observation of allele-specific VE in the phase 3 RTS,S
103 trial.⁴ Because our genotyping assay detects newly incident superinfections in individuals with
104 pre-existing infections, we performed a post hoc analysis of VE based on infection status at first

105 vaccination to test the common hypothesis cited in other recent studies that an erythrocytic
106 malaria infection during vaccination impairs development of a protective immune response.^{5,6}

107 **Methods**

108 Study Design and Sequence-Data Generation

109 As described fully in the primary analysis of the parent study evaluating protection against
110 clinical disease,³ participants 5–17 months in age were enrolled at study sites in Agogo, Ghana,
111 and Siaya, Kenya (750 per site), and randomly assigned into one of five vaccination groups
112 (1:1:1:1:1). The control rabies vaccination group was vaccinated at months 0, 1, and 2.
113 Participants in the RTS,S groups received two full doses at months 0 and 1 and either full doses
114 at months 2 and 20 (group R012-20), full doses at months 2, 14, 26, and 38 (group R012-14),
115 fractional doses at months 2, 14, 26, and 38 (group Fx012-14; early fourth dose), or fractional
116 doses at months 7, 20, and 32 (group Fx017-20; delayed third dose; **Fig. S1–S3** in the
117 Supplementary Appendix).

118 Participant samples were collected as dried blood spots (DBS) on Whatman FTA sample
119 cards at the baseline enrollment visit (M0), cross-sectionally at monthly intervals until study
120 month 20, and during febrile clinic visits. Blood smears were collected for microscopy-based
121 detection of infection. For asymptomatic individuals, blood smears were evaluated at a later
122 date and did not trigger treatment to clear infection. Participants meeting the primary or
123 secondary case definitions of malaria were treated according to the national guidelines of each
124 country, with the primary case definition being >5000 asexual parasites per μL and fever
125 (axillary temperature $\geq 37.5^\circ\text{C}$), and the secondary case definition being any parasitemia > 0
126 and fever or history of fever within 24 h of presentation.

127 We analyzed all DBS samples by extracting DNA and performing Illumina-based
128 amplicon sequencing of the *cs* C-terminus coding region (*cs*) and a comparably polymorphic
129 coding region for the antigen *sera2*. We defined distinct haplotypes as the combined genotype
130 of all nucleotide variants in a given amplicon sequence. Complexity of Infection (COI) was
131 defined as the maximum number of distinct haplotypes detected in a sample at either amplicon.
132 We declared a new parasite infection on a specific sampling date if at least one haplotype was
133 observed for either amplicon that had not been previously detected in the preceding three
134 samples from that individual. Haplotype diversity was high at both study sites for both the *cs* and
135 *sera2* amplicons (**Fig. S4** in the Supplementary Appendix). A full description of molecular
136 methods, data filtration, and sequence analysis is in the Supplementary Appendix. All MiSeq
137 data were submitted to the NCBI Sequence Read Archive (BioProject PRJNA983279).

138

139 Study Oversight

140 The trial (MAL-095; NCT03281291) and its parent study (MAL-094; NCT03276962) were
141 sponsored by GlaxoSmithKline Biologicals SA, the vaccine developer and manufacturer, and
142 funded by both GlaxoSmithKline Biologicals SA and the PATH Malaria Vaccine Initiative, which
143 received a grant from the Bill and Melinda Gates Foundation. The trial protocol was approved by
144 all relevant ethical review boards and signed or witnessed thumbprint informed consent was
145 obtained from the children's parents or guardians prior to participation.

146

147 Statistical Analysis

148 All analyses planned prior to the execution of this study are described in the Statistical Analysis
149 Plan (SAP) included in the Supplementary Appendix. In short, we first assessed VE of each
150 RTS,S regimen vs. rabies control and relative VE comparing RTS,S regimens head-to-head to
151 prevent the first new genotypic infection and to reduce the number of new genotypic infections.
152 These analyses were performed in parallel for the Exposed Set (ES) of participants who

153 received the first vaccine dose (**Fig. S2** in the Supplementary Appendix) and the Per-Protocol
154 Set (PP) of participants who received the first 3 doses per protocol and were in follow-up at 14
155 days after the third dose (**Fig. S3** in the Supplementary Appendix). We analyzed the follow-up
156 period from the first dose to the month 20 visit in the ES and from 14 days after the third dose to
157 a visit scheduled 12 months after the third dose in the PP.

158 To study vaccine effects on time to the first new infection, we defined VE as one minus
159 the hazard ratio (RTS,S vs. control) of the first new infection estimated using the Cox
160 proportional hazards model with 95% Wald confidence intervals (CIs) and two-sided Wald tests
161 of zero VE. For RTS,S head-to-head comparisons, relative VE was defined analogously
162 replacing the control with an active comparator regimen. Further, we estimated instantaneous
163 VE over time with 95% pointwise and simultaneous CIs using nonparametric kernel-smoothing⁷
164 and tested for variation in VE across time⁸. Cumulative incidence of the first new infection was
165 estimated using the transformed Nelson-Aalen estimator for the cumulative hazard function.

166 We measured vaccine effects on the number of new infections by the additive difference
167 (RTS,S vs. comparator) in the mean number of new infections. The infection count was defined
168 as unobserved if the number of missed visits or samples exceeded a specified threshold
169 (Supplementary Appendix). We assessed the mean difference by targeted maximum likelihood
170 estimation (TMLE)⁹ accounting for unobserved infection counts. Additionally, we employed
171 TMLE to estimate reverse cumulative distribution functions of the number of new infections in
172 each study group.

173 Besides overall VE, we assessed in the PP whether and how VE against the first new
174 infection depended on genotypic characteristics of infecting parasites using augmented inverse
175 probability weighting^{10,11} and their complete-case analogs¹² (details in Supplementary
176 Appendix).

177 Finally, we assessed whether baseline parasite positivity and/or infection risk modified
178 the effect of RTS,S on the time to the first new genotypic infection and the time to the first new

179 clinical malaria episode. Covariate-adjusted Cox proportional hazards models with separate
180 baseline hazards for each study site, employing 95% Wald CIs and Wald interaction tests, and
181 Nelson-Aalen-based cumulative incidence curves were used. We performed a sensitivity
182 ‘matching’ Cox analysis with stratified sampling, wherein baseline negative participants were
183 randomly sampled from the same randomization group and study site by matching baseline
184 positive participants on the date of the third vaccination to address potential confounding by low-
185 vs. high-transmission season. Additionally, a sensitivity analysis with E-values quantified the
186 robustness of evidence for baseline parasite positivity and M2-FOI causally modifying vaccine
187 efficacy (details in Supplementary Appendix).

188 All aforementioned analyses were performed on pooled data from both study sites as
189 well as separately within each site. Tests for VE departing from 0 were adjusted for multiplicity
190 separately within each analysis cohort, study site-pooled vs. -specific analysis, and each of the
191 three sets of treatment comparison types defined as follows: comparisons vs. the control
192 regimen other than the primary comparisons of each of Fx012-14 and Fx017-20 vs. control,
193 comparisons vs. the “standard” RTS,S regimen R012-20, and head-to-head comparisons of
194 novel RTS,S regimens (details in the Supplementary Appendix). For each multiplicity set, P-
195 value adjustments were implemented to control the familywise error rate (FWER) (Holm-
196 Bonferroni¹³) and the false discovery rate (FDR) (Q-values; Benjamini-Hochberg¹⁴). We defined
197 FWER statistical significance as an FWER-adjusted P-value ≤ 0.05 and FDR statistical
198 significance as a Q-value ≤ 0.2 together with an unadjusted P-value ≤ 0.05 . All P-values are
199 two-sided except P-values testing differential VE by 3D7 Hamming distances and by COI, which
200 are double one-sided.

201

202 **Results**

203 Participants and Genotypic Endpoints

204 The ES comprised 1,500 children (750 per study site), with 36,080 specimens collected
205 between the first dose and the month 20 visit and 35,456 (98.3%) with genotyping completed
206 (**Fig. S2** in the Supplementary Appendix). Of those, 5,078 (14.3%) were confirmed parasite-
207 positive, among which 3,937 (77.5%) were associated with a new infection. The PP comprised
208 1,332 children (687 in Agogo and 645 in Siaya), with 34,147 specimens collected during the PP
209 follow-up period (14 days to 12 months after the third dose) and 33,547 (98.2%) with genotyping
210 completed (**Fig. S3** in the Supplementary Appendix). Of those, 4,746 (14.1%) were confirmed
211 parasite-positive, among which 3,690 (77.7%) were associated with a new infection. In the ES
212 and PP, 1,030 (68.7%) and 763 (57.3%) participants, respectively, experienced the first new
213 genotypic infection during the respective follow-up. The median time from the first (third) dose to
214 the first new infection in the ES (PP) was 40.9 (37.0) weeks. The mean number of new
215 genotypic infections per individual was 2.9 and 1.5 in the ES and PP, respectively.

216

217 Vaccine Efficacy against First New Infection

218 VE of each RTS,S regimen vs. the control regimen was 25–31% (95% CI union, 9 to 43) in the
219 ES and 37–43% (95% CI union, 21 to 53) in the PP, each significantly different from zero (all
220 $P < 0.0033$ in the ES and < 0.001 in the PP) (**Fig. 1** and **Fig. S5** in the Supplementary Appendix).
221 No significant differences in the hazard rate of the first new infection were found in head-to-head
222 comparisons of RTS,S regimens (all $P > 0.32$) (**Fig. S6** in the Supplementary Appendix).
223 Instantaneous VE over time suggests that the full dose at month 2 may have provided a more
224 sustained protection than a fractional dose at month 2, as VE of Fx012-14 waned to zero by 7
225 months after the third dose (**Fig. S7** in the Supplementary Appendix).

226

227 Vaccine Efficacy to Reduce Number of New Infections

228 The mean number of new infections in RTS,S recipients was significantly lower than that in
229 control recipients in both the ES and PP (all $P < 0.001$) (**Fig. 2** and **Fig. S8** in the Supplementary
230 Appendix). In the ES, the mean new infection count during 20 months ranged between 2.6–3.0
231 among RTS,S recipients and was 4.1 among control recipients, with the mean difference
232 ranging -1.6 to -1.1 (95% CI union, -2.1 to -0.6). In the PP, the mean new infection count
233 between 14 days and 12 months after the third dose ranged between 1.4–1.5 among RTS,S
234 recipients and was 2.2 and 2.7 among control recipients between months 2.5–14 or 7.5–19,
235 respectively, with the mean difference ranging -1.3 to -0.8 (95% CI union, -1.6 to -0.4).

236

237 Haplotype Variation

238 RTS,S regimens diminished the COI of the first new infection compared to the control regimen
239 in the PP (**Fig. 3A** and **3C**). Moreover, RTS,S regimens exhibited a significantly greater
240 reduction in the risk of more highly polyclonal first new infections (**Fig. 3B** and **3D**). The
241 estimated risk reduction of pooled R012-14, R012-20, and Fx012-14 vs. control was 29% (95%
242 CI, 13 to 42) against single-haplotype first new infections and 76% (95% CI, 58 to 86) against
243 first new infections with 5 haplotypes ($P < 0.001$ for increasing risk reduction with COI).

244 The genotypic sieve analysis was underpowered given the low 3D7 prevalence and
245 small endpoint counts. No evidence was found for differential VE against the first new infection
246 with a perfect amino acid residue match vs. mismatch to the 3D7 vaccine strain in the *cs* C-
247 terminus full amplicon or haplotypic regions (**Fig. S9** in the Supplementary Appendix). There
248 was a non-significant trend of a VE decline with an increasing degree of residue mismatch to
249 3D7 in the *cs* C-terminus (**Figure S10** in the Supplementary Appendix). Scanning individual
250 polymorphic amino acid positions, we found hypothesis-generating signals of differential VE of
251 Fx012-14 against first new infection strains with a match vs. mismatch to a 3D7 residue at *cs* C-
252 terminus codon positions 322, 324, and 327 in Th2R (**Fig. S11–S14** in the Supplementary
253 Appendix).

254

255 Vaccine Efficacy Modification by Baseline Parasite Positivity and Intercurrent New Infection

256 In the PP, 11.6% of participants (7.4% in Agogo and 16.0% in Siaya) were parasite positive at
257 baseline by microscopy and/or genotypic assay. The control-group incidence rate of the first
258 new infection was nearly three times higher in baseline positive (3.0 per person-year at risk
259 [PYR]) than baseline negative participants (1.2 per PYR), suggesting a correlation between
260 baseline positivity and infection risk; therefore, we also analyzed the cumulative number of new
261 genotypic infections (force of infection; FOI) detected after the first vaccination visit and by the
262 month 2 visit (M2-FOI). This covariate is an aggregate proxy of individual-level infection risk due
263 to many factors including seasonal transmission effects, local geography, susceptibility to
264 mosquito bites, and malaria prevention use. M2-FOI could potentially confound the VE-
265 modifying effect of baseline positivity, given that it was correlated with baseline positivity and the
266 calendar date of the first vaccination (**Fig. S15–S16** in the Supplementary Appendix). We also
267 accounted for such potential confounding by adjusting for the indicator of the onset of
268 antimalarial drug treatment between the first vaccination visit and the month 2 visit (M2-mal-tx),
269 which correlated with baseline positivity (**Fig. S17** in the Supplementary Appendix). Additional
270 VE-modification analyses were conducted adjusting for M2-FOI and M2-mal-tx, an adjustment
271 with minimal risk of post-randomization selection bias because vaccination had no discernible
272 effect on M2-FOI or M2-mal-tx (**Fig. S18–S19** in the Supplementary Appendix). Adjusting for
273 M2-FOI, M2-mal-tx, sex, and age, VE of pooled R012-14, R012-20, and Fx012-14 vs. control to
274 prevent the first new genotypic infection in the PP was 37% (95% CI, 23 to 48%) among
275 baseline negative and 68% (95% CI, 50 to 80%) among baseline positive participants
276 (interaction $P=0.0053$) (**Fig. 4**; model M2-PP in **Fig. S20** in the Supplementary Appendix). VE
277 modification by baseline positivity persisted when restricted to the early follow-up period
278 between 14 days and 4.5 months after the third dose (**Fig. S21** in the Supplementary Appendix)
279 (interaction $P=0.083$), a period exhibiting relatively little waning of VE. The evidence for baseline

280 positivity as a modifier of VE was consistent across the two study sites, the individual RTS,S
281 regimens with dosing at M0, 1, 2, and the full PP vs. sensitivity ‘third vaccination matching’
282 analysis (**Fig. S22–S24** in the Supplementary Appendix).

283 As an indicator of intercurrent malaria infection between dose 1 and dose 3, M2-FOI has
284 a distinct interpretation compared to baseline positivity, motivating an exploratory analysis of
285 whether M2-FOI itself modifies VE. Adjusting for baseline positivity, M2-mal-tx, sex, and age,
286 VE of the same pooled RTS,S groups vs. control against the first new genotypic infection was
287 36% (95% CI, 22 to 48%) among PP participants with M2-FOI = 0 and 57% (95% CI, 39 to
288 69%) among PP with M2-FOI > 0 (interaction P=0.059) (**Fig. 5**; model M6-PP in **Fig. S20** in the
289 Supplementary Appendix). VE modification evidence from a series of Cox models involving both
290 baseline positivity and M2-FOI, including model quality assessment, is summarized in **Fig. S20**
291 in the Supplementary Appendix for the genotypic infection endpoint. A sensitivity analysis,
292 reported in the Supplementary Appendix, concluded that the result of VE modification by
293 baseline positivity was robust to unmeasured confounding.

294 We do not report the impact of either baseline positivity or M2-FOI on VE against the first
295 new clinical malaria episode. Inference of this causal interaction effect is confounded by a
296 differential propensity of first clinical episodes arising due to persistent asymptomatic infections
297 acquired before the third vaccination, which are much more common in the baseline positive
298 and M2-FOI > 0 subgroups (**Table S5** in the Supplementary Appendix).

299

300 **Discussion**

301 The use of genotypically determined infection endpoints in this study has demonstrated
302 unambiguously for the first time that RTS,S achieves some or all of the VE observed through
303 blocking of infections before they reach the blood stage, with the RTS,S groups exhibiting a
304 reduced number of new infections (**Fig. 2**) and a reduced risk of more highly polyclonal first

305 infections (**Fig. 3**). While the previous analysis of parasite genotypic features we performed on
306 specimens from the RTS,S phase 3 trial suggested this in the form of reduced COI,⁴ that study
307 only analyzed specimens from the first cases meeting the primary clinical case definition.

308 The genotypically determined infection endpoints yielded findings generally concordant
309 with the previous analysis of clinical disease endpoints with regard to the effects of RTS,S
310 vaccine dosage and regimen. While all RTS,S dosage regimens offer significant VE, none of the
311 regimens is superior for the follow-up period we examined. The genotypic endpoints we
312 examined suggest lower instantaneous VE in the Fx012-14 group several months after the third
313 dose (Fig. S7 in the Supplementary Appendix), suggesting that fractional dose regimens may
314 offer slightly less protection than full dose regimens administered on the same schedule.

315 Additionally, this study demonstrates several ways in which genotypically determined
316 infection endpoints complement clinical disease or microscopy-based infection endpoints.
317 Importantly, we observed that VE against the first new genotypically detected infection was
318 higher in participants who were baseline parasite-positive (asymptomatically infected with
319 malaria during their first vaccination). Participants who experienced more infections between
320 their first vaccination and month 2 visit (M2-FOI) did not exhibit abrogated VE and trended
321 towards greater protection. This suggests that active infection, and/or higher risk of infection,
322 potentiate RTS,S VE. Because baseline infection status and M2-FOI are correlated and these
323 features were not randomized in the study design, distinguishing their relative impacts is difficult
324 from the current data. Further, we cannot presently distinguish whether variation in infection risk
325 among participants is due to environmental, immunological, or other factors. However, active
326 infections at the time of first vaccination could affect VE by the prior priming of CS-specific T-
327 helper cells provided by natural infection, resulting in enhanced production of protective
328 antibodies and/or a more effective cellular immune response during the liver stage. Similarly,
329 the non-significant trend towards greater VE observed in participants with M2-FOI > 0 could be

330 driven by repeated natural exposure to CS antigen from infectious mosquito bites as a form of
331 heterologous prime-boost.

332 The observation of increased RTS,S protection in baseline-infected/M2-FOI > 0
333 participants is unexpected. A large number of studies have documented immunosuppressive
334 effects of acute or asymptomatic malaria infection in various human or rodent model contexts^{15–}
335 ²⁰, and these observations have led to the hypothesis that erythrocytic-stage malaria infection at
336 the time of vaccination may compromise the development of an efficacious immune response,
337 measured at the level of either clinical disease⁵ or molecularly detected infection.⁶ However, a
338 recent analysis of RTS,S efficacy in the phase 3 clinical trial found that protection against
339 clinical malaria was unaffected by infection status during vaccination.²¹ Our work is the first to
340 demonstrate a positive association between erythrocytic infection present at the first vaccination
341 and VE against infection, and indicates that discordant findings in studies focusing on malaria-
342 naive adults⁶ or mouse models²⁰ may reflect fundamentally different mechanisms of pre-
343 erythrocytic immunity development. Future studies will be required to understand this apparent
344 discordance.

345 There are several important consequences of the observation of greater RTS,S VE in
346 association with baseline parasite positivity and infection risk. First, this finding indicates that
347 future studies of the efficacy of RTS,S and other candidate malaria vaccines may need to take
348 into account local transmission level and/or heterogeneity in infection risk among participants,
349 as differential VE against infection and/or clinical disease as a function of baseline infection
350 status or infection risk could influence vaccine deployment strategy. Second, this finding
351 motivates the inclusion of genotypic endpoints in future intervention studies to further assess the
352 effects of baseline infection status and molecular FOI, as well as immune assays to understand
353 the mechanism of the protective effect.²² Future studies should directly address the impact of
354 baseline positivity and infection risk on VE against clinical disease, which we do not report here
355 because the interaction effect of treatment and the potential VE modifier is confounded by

356 differential opportunity among subgroups for the first clinical cases to be associated with
357 asymptomatic infections acquired before the third vaccination, which may increase the risk of
358 subsequent clinical disease.²³ Additionally, this finding could lead designers of future vaccine
359 and monoclonal antibody (mAb) field trials to re-evaluate the practice of diagnosing and clearing
360 pre-existing malaria infections from subjects during enrollment, a common approach^{24–26} that
361 may limit the approved use of an intervention to uninfected recipients if it is later licensed.

362 Genotyping the monthly cross-sectional samples collected from all subjects in this study
363 has provided an unprecedented view of asymptomatic and polyclonal infection dynamics in a
364 natural setting. The evaluation of future malaria interventions with comparable data will enable
365 direct measurement of their potential not only to mitigate clinical cases, but also to achieve local
366 disease elimination.

367

368 **Disclosure**

369 The findings and conclusions in this article are those of the authors and do not necessarily
370 represent the views of the U.S. Centers for Disease Control and Prevention or the U.S.
371 Department of Health and Human Services.

372 **Trademark**

373 AS01 is a trademark owned by or licensed to the GSK group of companies.

374 **Conflicts of Interest**

375 LDM received grants from the Bill and Melinda Gates Foundation and KfW/BMBF (German
376 Federal Ministry of Education and Research) through her institution. CKL received a grant
377 from KfW/BMBF (German Federal Ministry of Education and Research) and a grant from Bill
378 and Melinda Gates Foundation. DFW acted as a PI on this MAL-095 study funded by a PATH
379 grant paid to Harvard University, which also supported DEN, AME, BLM, SFS, and AK. DFW
380 is also Chair of the MPAG (Malaria Policy Advisory Group) that advises the WHO on all

381 malaria policy. PBG discloses a PATH subaward from Harvard for statistical analysis
382 contributing to salary support for PBG, MJ, and LL. AME, LL, AK,BS, NSH, DB, SAdjei, TA,
383 SA, DA, DKB, PBYB, SE, NF, JG, SKK, KO, AMS, NW, CFO declare no conflict of interest.
384 ML, FR, OO-A are employees of GSK.ML, FR, and OO-A own shares in GSK. The authors
385 declare no other financial and non-financial relationships and activities.

386

387 **Acknowledgements**

388 Funding for this trial and publication was provided by GlaxoSmithKline Biologicals SA (study
389 sponsor) and by PATH, an international public health organization, through grants awarded to
390 PATH's Center for Vaccine Innovation and Access by the Bill & Melinda Gates Foundation and
391 the German Federal Ministry of Education and Research (the latter administered through the
392 KfW Development Bank). The authors and trial partners thank the study participants and their
393 parents/caregivers, and the RTS,S MAL-094 Study Group for their participation and support of
394 malaria clinical research. This work was also partially supported by the National Institute of
395 Allergy and Infectious Diseases, NIH, under award R37AI054165 (to PBG). We wish to thank
396 the Broad Institute Genomics Platform for sample processing and data generation, in particular,
397 Jody Camarata, Natasha Smith, and Rachael Barry. We also thank Susanna Hamilton, Chad
398 Max, and Kalyn Hubbard for product management and Nithya Swaminathan for project
399 management at the Broad Institute. We thank the following PATH colleagues: Scott Gregory for
400 project management and Karen Ivinson for IRB submissions. We thank Anne Bollaerts (GSK)
401 for data analysis and Hildegard Lemaire for sample management at GSK. Business & Decision
402 Life Sciences platform provided editorial assistance and manuscript coordination, on behalf of
403 GSK.

404 **Contributions:**

405 MJ, ML, LDM, SAdjei, TA, DA, DKB, PBYB, SKK, KO, AMS, NW, CFO, CKL, BLM, DFW, PBG,
406 and DEN contributed to the study design and methods. AME, AK, SAdjei, TA, SAnderson, DKB,
407 PBYB, SE, NF, JG, SKK, KO, FR, AMS, NW, OO-A, DFW, and DEN were responsible for data
408 acquisition. MJ, AME, LL, SFS, ML, BS, NSH, DB, LDM, DA, DKB, PBYB, SKK, KO, AMS, NW,
409 CFO, CKL, BLM, DFW, PBG, and DEN performed data analysis, and/or data interpretation. All
410 authors read and edited the manuscript. All authors approved the final version and the decision
411 to submit the manuscript. All authors had full access to all the data and had final responsibility
412 for the decision to submit for publication.

413

414 **References**

415

- 416 1. World malaria report 2022 [Internet]. [cited 2023 May 17]; Available from:
417 <https://www.who.int/publications-detail-redirect/9789240064898>
- 418 2. Galatas B, Bassat Q, Mayor A. Malaria Parasites in the Asymptomatic: Looking for the Hay
419 in the Haystack. *Trends Parasitol* 2016;32(4):296–308.
- 420 3. Samuels AM, Ansong D, Kariuki SK, et al. Efficacy of RTS,S/AS01E malaria vaccine
421 administered according to different full, fractional, and delayed third or early fourth dose
422 regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b,
423 randomised controlled trial. *Lancet Infect Dis* 2022;22(9):1329–42.
- 424 4. Neafsey DE, Juraska M, Bedford T, et al. Genetic Diversity and Protective Efficacy of the
425 RTS,S/AS01 Malaria Vaccine. *N Engl J Med* 2015;373(21):2025–37.
- 426 5. Oneko M, Steinhardt LC, Yego R, et al. Safety, immunogenicity and efficacy of PfSPZ
427 Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-
428 controlled phase 2 trial. *Nat Med* 2021;27(9):1636–45.
- 429 6. Murphy SC, Deye GA, Sim BKL, et al. PfSPZ-CVac efficacy against malaria increases
430 from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A
431 randomized, placebo-controlled trial with controlled human malaria infection. *PLoS Pathog*
432 2021;17(5):e1009594.
- 433 7. Gilbert PB, Wei LJ, Kosorok MR, Clemens JD. Simultaneous inferences on the contrast of
434 two hazard functions with censored observations. *Biometrics* 2002;58(4):773–80.
- 435 8. Grambsch PM, Therneau TM. Proportional Hazards Tests and Diagnostics Based on
436 Weighted Residuals. *Biometrika* 1994;81(3):515–26.
- 437 9. Porter KE, Gruber S, van der Laan MJ, Sekhon JS. The relative performance of targeted
438 maximum likelihood estimators. *Int J Biostat* 2011;7(1):31.
- 439 10. Juraska M, Gilbert PB. Mark-specific hazard ratio model with missing multivariate marks.
440 *Lifetime Data Anal* 2016;22(4):606–25.
- 441 11. Heng F, Sun Y, Gilbert PB. Estimation and Hypothesis Testing of Strain-Specific Vaccine
442 Efficacy with Missing Strain Types, with Applications to a COVID-19 Vaccine Trial
443 [Internet]. 2022 [cited 2023 Mar 4]; Available from: <http://arxiv.org/abs/2201.08946>
- 444 12. Juraska M, Gilbert PB. Mark-specific hazard ratio model with multivariate continuous

- 445 marks: an application to vaccine efficacy. *Biometrics* 2013;69(2):328–37.
446 13. Holm S. A Simple Sequentially Rejective Multiple Test Procedure. *Scand J Stat*
447 1979;6(2):65–70.
448 14. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
449 Approach to Multiple Testing. *J R Stat Soc Ser B Methodol* 1995;57(1):289–300.
450 15. Greenwood BM, Bradley-Moore AM, Bryceson AD, Palit A. Immunosuppression in children
451 with malaria. *Lancet Lond Engl* 1972;1(7743):169–72.
452 16. McBride JS, Micklem HS. Immunosuppression in murine malaria. II. The primary response
453 to bovine serum albumin. *Immunology* 1977;33(2):253–9.
454 17. Whittle HC, Brown J, Marsh K, et al. T-cell control of Epstein-Barr virus-infected B cells is
455 lost during *P. falciparum* malaria. *Nature* 1984;312(5993):449–50.
456 18. Ho M, Webster HK, Looareesuwan S, et al. Antigen-specific immunosuppression in human
457 malaria due to *Plasmodium falciparum*. *J Infect Dis* 1986;153(4):763–71.
458 19. Bejon P, Mwacharo J, Kai O, et al. The induction and persistence of T cell IFN-gamma
459 responses after vaccination or natural exposure is suppressed by *Plasmodium falciparum*.
460 *J Immunol* 2007;179(6):4193–201.
461 20. Keitany GJ, Kim KS, Krishnamurty AT, et al. Blood Stage Malaria Disrupts Humoral
462 Immunity to the Pre-erythrocytic Stage Circumsporozoite Protein. *Cell Rep*
463 2016;17(12):3193–205.
464 21. Bell GJ, Gyaase S, Goel V, et al. Malaria Transmission Intensity and Parasitemia during
465 the Three-Dose RTS,S/AS01 Vaccination Series do not Reduce Magnitude of Antibody
466 Response nor Efficacy Against the First Case of Malaria [Internet]. In Review; 2023 [cited
467 2023 Jun 8]. Available from: <https://www.researchsquare.com/article/rs-2960373/v1>
468 22. Mueller I, Schoepflin S, Smith TA, et al. Force of infection is key to understanding the
469 epidemiology of *Plasmodium falciparum* malaria in Papua New Guinean children. *Proc Natl*
470 *Acad Sci U S A* 2012;109(25):10030–5.
471 23. Sumner KM, Mangeni JN, Obala AA, et al. Impact of asymptomatic *Plasmodium falciparum*
472 infection on the risk of subsequent symptomatic malaria in a longitudinal cohort in Kenya.
473 *eLife* 2021;10:e68812.
474 24. Sissoko MS, Healy SA, Katile A, et al. Safety and efficacy of PfSPZ Vaccine against
475 *Plasmodium falciparum* via direct venous inoculation in healthy malaria-exposed adults in
476 Mali: a randomised, double-blind phase 1 trial. *Lancet Infect Dis* 2017;17(5):498–509.
477 25. Kayentao K, Ongoiba A, Preston AC, et al. Safety and Efficacy of a Monoclonal Antibody
478 against Malaria in Mali. *N Engl J Med* 2022;387(20):1833–42.
479 26. Sissoko MS, Healy SA, Katile A, et al. Three dose regimen of PfSPZ Vaccine protects
480 adult Malians against *Plasmodium falciparum* through an intense transmission season: a
481 randomised, controlled phase I trial. *Lancet Infect Dis* 2022;22(3):377–89.

482

483 **Figure Captions**

484 Figure 1. Cumulative incidence and vaccine efficacy against the first new genotypic infection for
485 the PP cohort. First new genotypic infection (A) between 14 days after month 2 through month
486 14 for R012-14 plus R012-20 and Fx012-14 vs. the control regimen and (B) between 14 days
487 after month 7 through month 19 for Fx017-20 vs. the control regimen. (C) Forest plot of vaccine

488 efficacies against the first new infection vs. the control regimen. PYR: person-year at risk; VE:
489 vaccine efficacy; CI: confidence interval; PP: Per Protocol cohort; No: number.

490

491 Figure 2. Reverse cumulative distribution function and vaccine effect on the number of new
492 molecular infections in the Per-Protocol (PP) cohort (A) between 14 days after month 2 through
493 month 14 for R012-14 plus R012-20 and Fx012-14 vs. the control regimen and (B) between 14
494 days after month 7 through month 19 for Fx017-20 vs. the control regimen. (C) Forest plot of
495 vaccine effects on the mean number of new infections vs. the control regimen. CI: confidence
496 interval; PP: Per Protocol cohort; No: number; Diff: Difference.

497

498 Figure 3. Comparisons of Complexity of infection (COI) of first new genotypic infections between
499 the pooled R012-14, R012-20, and Fx012-14 RTS,S regimens vs. the control regimen (for new
500 infections between 14 days after month 2 through month 13) and Fx017-20 vs. the control
501 regimen (for new infections between 14 days after month 7 through month 19) for the Per-
502 Protocol (PP) cohort: (A), (C) frequencies and (B), (D) risk reduction ($1 - \text{hazard ratio}$) against
503 the first new genotypic infection with a given level of COI.

504

505 Figure 4. (A) Cumulative incidence and (B) vaccine efficacy against the first new genotypic
506 infection between 14 days after month 2 through month 14 for the pooled R012-14, R012-20,
507 and Fx012-14 RTS,S regimens vs. the control regimen for the Per-Protocol (PP) cohort by
508 baseline malaria infection status while adjusting for month 2 force of infection (M2-FOI). PYR:
509 person-year at risk; VE: vaccine efficacy; CI: confidence interval; No: number.

510

511 Figure 5. (A) Cumulative incidence and (B) vaccine efficacy against the first new genotypic
512 infection between 14 days after month 2 through month 14 for the pooled R012-14, R012-20,
513 and Fx012-14 RTS,S regimens vs. the control regimen for the per-protocol (PP) cohort by

514 month 2 FOI (M2-FOI) = 0 vs. > 0. PYR: person-year at risk; VE: vaccine efficacy; CI:

515 confidence interval; No: number; M2-FOI: month 2 force of infection.

516

517




Figure 1. Cumulative incidence and vaccine efficacy against the first new genotypic infection for the PP cohort.






Figure 2. Reverse cumulative distribution function and vaccine effect on the number of new molecular infections in the PP cohort.


A



B



C



D





Figure 3. Comparisons of Complexity of infection (COI) of first new genotypic infections between the pooled R012-14, R012-20, and Fx012-14 RTS,S regimens vs. the control regimen (for new infections between 14 days after month 2 through month 13) and Fx017-20 vs. the control regimen (for new infections between 14 days after month 7 through month 19) for the Per-Protocol (PP) cohort: (A), (C) frequencies and (B), (D) risk reduction (1 – hazard ratio) against the first new genotypic infection with a given level of COI.

A



No. At Risk for First New Infection									
Control, Baseline Positive	31	20	12	8	7	4	3	1	0
RTS,S Pooled, Baseline Positive	98	83	76	62	54	38	31	3	0
Control, Baseline Negative	234	197	168	149	123	102	77	7	1
RTS,S Pooled, Baseline Negative	696	642	581	502	447	374	292	45	1


Cumulative No. of First New Infections									
Control, Baseline Positive	0	11	18	22	23	26	27	28	28
RTS,S Pooled, Baseline Positive	0	15	22	34	42	57	63	68	68
Control, Baseline Negative	0	31	61	78	105	125	142	148	148
RTS,S Pooled, Baseline Negative	0	45	97	165	219	286	340	372	374

Figure 4. (A) Cumulative incidence and (B) vaccine efficacy against the first new genotypic infection between 14 days after month 2 through month 14 for the pooled R012-14, R012-20, and Fx012-14 RTS,S regimens vs. the control regimen for the Per-Protocol (PP) cohort by baseline malaria infection status while adjusting for month 2 force of infection (M2-FOI). PYR: person-year at risk; VE: vaccine efficacy; CI: confidence interval; No: number.

B

Baseline Positivity	No. of First New Infections (Incidence per PYR)	VE (%) (95% CI)	Interaction P-value
Negative	374 (0.85) vs. 148 (1.16)	36.5 (23.0, 47.6)	0.0053
Positive	68 (1.25) vs. 28 (3.02)	68.0 (50.1, 79.5)	

A



No. At Risk for First New Infection

Control, M2-FOI > 0	53	36	22	17	12	8	6	1	0
RTS,S Pooled, M2-FOI > 0	154	125	111	89	78	62	44	5	0
Control, M2-FOI = 0	212	181	158	140	118	98	74	7	1
RTS,S Pooled, M2-FOI = 0	640	600	546	475	423	350	279	43	1

Cumulative No. of First New Infections

Control, M2-FOI > 0	0	17	30	35	40	44	46	48	48
RTS,S Pooled, M2-FOI > 0	0	29	45	63	74	90	105	113	114
Control, M2-FOI = 0	0	25	49	65	88	107	123	128	128
RTS,S Pooled, M2-FOI = 0	0	31	74	136	187	253	298	327	328

Figure 5. (A) Cumulative incidence and (B) vaccine efficacy against the first new genotypic infection between 14 days after month 2 through month 14 for the pooled R012-14, R012-20, and Fx012-14 RTS,S regimens vs. the control regimen for the per-protocol (PP) cohort by month 2 FOI (M2-FOI) = 0 vs. > 0. PYR: person-year at risk; VE: vaccine efficacy; CI: confidence interval; No: number; M2-FOI: month 2 force of infection.

B

M2-FOI	No. of First New Infections (Incidence per PYR)	VE (%) (95% CI)	Interaction P-value
0	328 (0.79) vs. 128 (1.07)	36.1 (21.4, 48.0)	0.059
1-3	114 (1.42) vs. 48 (2.79)	56.5 (38.7, 69.1)	